Signe Hässler
YOU?
Author Swipe
View article: Temporal trajectories and DMARD therapy retention of rheumatoid arthritis patients with different autoimmune and inflammatory comorbidity profiles: a retrospective analysis
Temporal trajectories and DMARD therapy retention of rheumatoid arthritis patients with different autoimmune and inflammatory comorbidity profiles: a retrospective analysis Open
Comorbidity trajectories in RA are associated with DMARD persistence, reflecting distinct subgroups with potential theranostic relevance. These results should be confirmed through a prospective study on DMARD-initiating patients.
View article: Immunological Profiling suggests an Association between Treg dysfunction and Pain in Knee Osteoarthritis
Immunological Profiling suggests an Association between Treg dysfunction and Pain in Knee Osteoarthritis Open
Background Pain is the hallmark symptom of osteoarthritis (OA) and its biological drivers remain poorly understood. While the role of innate immunity in OA has been extensively studied, the involvement of adaptive immunity, in particular r…
View article: Autoimmune and inflammatory comorbidity patterns in rheumatoid arthritis: temporal trajectories and impact on persistence on DMARD therapy
Autoimmune and inflammatory comorbidity patterns in rheumatoid arthritis: temporal trajectories and impact on persistence on DMARD therapy Open
Objective Patients with immunological diseases exhibit distinct comorbidity patterns, categorized into low comorbidity, polyautoimmunity, and polyinflammation clusters. This retrospective cohort study aimed to validate these profiles in rh…
View article: Immunological Profiling in Knee Osteoarthritis: Treg Dysfunction as Key Driver of Pain
Immunological Profiling in Knee Osteoarthritis: Treg Dysfunction as Key Driver of Pain Open
Pain is the hallmark symptom of osteoarthritis (OA) and its biological drivers remain poorly understood. While the role of innate immunity in OA has been extensively studied, the involvement of adaptive immunity, in particular regulatory T…
View article: Clinical correlates of lifetime and current comorbidity patterns in autoimmune and inflammatory diseases
Clinical correlates of lifetime and current comorbidity patterns in autoimmune and inflammatory diseases Open
In this study, we have uncovered three distinct comorbidity profiles among AID patients. These profiles suggest the presence of distinct etiopathogenic mechanisms underlying these subgroups. Validation, longitudinal stability assessment, a…
View article: Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritis
Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritis Open
Background Although B-cell depleting therapy in rheumatoid arthritis (RA) is clearly effective, response is variable and does not correlate with B cell depletion itself. Methods The B-cell receptor (BCR) repertoire was prospectively analyz…
View article: Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies
Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies Open
Importance There are conflicting data on the association of antidrug antibodies with response to biologic disease–modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis (RA). Objective To analyze the association of antidrug antibo…
View article: POS0630 ANTIDRUG ANTIBODIES ARE NEGATIVELY ASSOCIATED WITH RESPONSE TO BIOLOGICAL DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS OF THE ABIRISK STUDY
POS0630 ANTIDRUG ANTIBODIES ARE NEGATIVELY ASSOCIATED WITH RESPONSE TO BIOLOGICAL DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS OF THE ABIRISK STUDY Open
View article: Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts
Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts Open
Objectives Around 30% of patients with rheumatoid arthritis (RA) do not respond to tumour necrosis factor inhibitors (TNFi). We aimed to predict patient response to TNFi using machine learning on simple clinical and biological data. Method…
View article: A Genetic Association Test Accounting for Skewed X-Inactivation With Application to Biotherapy Immunogenicity in Patients With Autoimmune Diseases
A Genetic Association Test Accounting for Skewed X-Inactivation With Application to Biotherapy Immunogenicity in Patients With Autoimmune Diseases Open
Despite being assayed on commercialized DNA chips, the X chromosome is commonly excluded from genome-wide association studies (GWAS). One of the reasons is the complexity to analyze the data taking into account the X-chromosome inactivatio…
View article: Definition of erythroid cell‐positive blood transcriptome phenotypes associated with severe respiratory syncytial virus infection
Definition of erythroid cell‐positive blood transcriptome phenotypes associated with severe respiratory syncytial virus infection Open
Biomarkers to assess the risk of developing severe respiratory syncytial virus (RSV) infection are needed. We conducted a meta‐analysis of 490 unique profiles from six public RSV blood transcriptome datasets. A repertoire of 382 well‐chara…
View article: Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium
Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium Open
In our study, we found that immunosuppressants and antibiotics were associated with decreased risk of ADA development, whereas tobacco smoking and infections during the study were associated with increased risk. We found that the HLA-DQA1*…
View article: Le microbiote : promoteur de la différenciation des lymphocytes T CD8 mémoires
Le microbiote : promoteur de la différenciation des lymphocytes T CD8 mémoires Open
End of the road for the « homosexuality gene »Evidence for a "homosexuality gene" was claimed in the early 1990's on the basis of linkage studies that, by current criteria, were woefully underpowered.Indeed, follow up studies gave contradi…
View article: A Machine Learning Approach for High-Dimensional Time-to-Event Prediction With Application to Immunogenicity of Biotherapies in the ABIRISK Cohort
A Machine Learning Approach for High-Dimensional Time-to-Event Prediction With Application to Immunogenicity of Biotherapies in the ABIRISK Cohort Open
Predicting immunogenicity for biotherapies using patient and drug-related factors represents nowadays a challenging issue. With the growing ability to collect massive amount of data, machine learning algorithms can provide efficient predic…
View article: Assessing the effect of genetic markers on drug immunogenicity from a mechanistic model-based approach
Assessing the effect of genetic markers on drug immunogenicity from a mechanistic model-based approach Open
View article: Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A
Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A Open
Replacement therapy in severe hemophilia A leads to factor VIII (FVIII) inhibitors in 30% of patients. Factor VIII gene (F8) mutation type, a family history of inhibitors, ethnicity and intensity of treatment are established risk factors, …
View article: Identification of erythroid cell positive blood transcriptome phenotypes associated with severe respiratory syncytial virus infection
Identification of erythroid cell positive blood transcriptome phenotypes associated with severe respiratory syncytial virus infection Open
Biomarkers to assess the severity of acute respiratory syncytial virus (RSV) infection are needed. We conducted a meta-analysis of 490 unique profiles from six public RSV blood transcriptome datasets. A repertoire of 382 well-characterized…
View article: Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis
Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis Open
View article: Monocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patients
Monocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patients Open
Multiple sclerosis (MS) is an autoimmune disease characterized by CNS inflammation leading to demyelination and axonal damage. IFN-β is an established treatment for MS; however, up to 30% of IFN-β-treated MS patients develop neutralizing a…
View article: A score test for comparing cross-sectional survival data with a fraction of non-susceptible patients and its application in clinical immunology
A score test for comparing cross-sectional survival data with a fraction of non-susceptible patients and its application in clinical immunology Open
In a wide range of scenarios, simulation results show interesting improvements in power for the proposed score test compared to the logrank-type test in most of the configurations we investigated. In a cross-sectional study of drug immunog…
View article: Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results
Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results Open
Antibodies against biopharmaceuticals (anti-drug antibodies, ADA) have been a well-integrated part of the clinical care of multiple sclerosis (MS) in several European countries. ADA data generated in Europe during the more than 10 years of…
View article: Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis
Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis Open
Immunogenicity of biopharmaceutical products in multiple sclerosis is a frequent side effect which has a multifactorial etiology. Here we study associations between anti-drug antibody (ADA) occurrence and demographic and clinical factors. …